[Tumor-inhibiting agents. 8. 5-Aminomethylated barbituric acid derivatives].
In view of the tumor inhibitory activity of various pyrimidine derivatives, investigations aimed at the structure modification of barbituric acids were performed. In accordance with the aminomethinylation principle, barbituric acids (2) are converted into 5-formimidoylbarbituric acids (4) by s-triazine (1). Aside from the free barbituric acid (2a), both 1-substituted (2b,  d, and f) and 1,3-di-substituted (2c, e, and g) barbituric acids are amenable to this reaction. After introduction of the formimidoyl group into 5-position of the barbituric acid ring system, marked tumor inhibitory effects against lymphoma, lymphocytical leukemia, and luekemia L-1210, are ascertainable.
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001463:Barbiturates / Q000627:therapeutic use*; D007939:Leukemia L1210 / Q000188:drug therapy; D007945:Leukemia, Lymphoid / Q000188:drug therapy; D008223:Lymphoma / Q000188:drug therapy; D051379:Mice; D013329:Structure-Activity Relationship
D000970:Antineoplastic Agents; D001463:Barbiturates
Tumorhemmende Wirkstoffe. 8. Mitteilung: 5-Aminomethinylierte Barbitursäurederivate).